Multimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Tumors

Seminars in Oncology

Volumn 34, Issue 2, 2007, Pages 129-134

  Fernando, Shaneli A ^a   Sandler, Howard M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ARTICLE; BLADDER TUMOR; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; CYSTECTOMY; HUMAN; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PELVIS LYMPH NODE; PRIORITY JOURNAL; QUALITY OF LIFE; STANDARD; TRANSURETHRAL RESECTION;

COMBINED MODALITY THERAPY; HUMANS; LYMPH NODE EXCISION; NEOPLASM INVASIVENESS; PELVIS; QUALITY OF LIFE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33947199703     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.12.009     Document Type: Article

References (38)

1. Herr H.W., Cookson M.S., and Soloway S.M. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 156 (1996) 1286-1287
2. Waehre H., Ous S., Klevmak B., et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 72 (1993) 3044-3051
3. Houseset M., Maulard C., Chretien Y., et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: A prospective study. J Clin Oncol 1 (1993) 2150-2157
4. Sauer R., Birkenhake S., Kuhn R., et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncolo Biol Phys 40 (1998) 121-127
5. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy and Oncology Group 89-03. J Clin Oncol 16 (1998) 3576-3583
6. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60 (2002) 62-68
7. Solsana E., Iberra I., Ricos J.V., et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Prospective study. J Urol 147 (1992) 1513-1515
8. Herr H.W. Conservative management of muscle infiltrating bladder cancer: Prospective experience. J Urol 138 (1987) 1162-1163
9. Dunst J., Sauer R., Schrott M., et al. Organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys 30 (1994) 261-266
10. Dunst J., Rodel C., Zietman A., et al. Bladder preservation in muscle invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol 20 (2001) 24-32
11. Gospodarowicz M., Hawkins G., Rawlings J., et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 142 (1989) 1448-1453
12. Duncan W., and Quilty P.M. The results of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol 7 (1986) 299-310
13. Shipley W.U., and Rose M.A. Bladder cancer: The selection of patients for treatment by full dose irradiation. Cancer 55 (1985) 2278-2284
14. Miller L.S. Bladder cancer: Superiority of preoperative radiation in cystectomy in clinical stage B2 and C. Cancer 39 (1977) 973-980
15. Horwich A., Pendlebur S., and Dearnaley D. Organ conservation in bladder cancer. Eur J Cancer 31 suppl 6 (1995) 208-209
16. Sell A., Jakobsen A., Nerstrom B., et al. Treatment of advanced bladder cancer category T2, T3, and T4a. A randomized multicenter study of preoperative radiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. Scand J Urol Nephrol 138 suppl (1991) 193-201
17. Horwich A., Dearnaley D., Huddart R., et al. A randomized trial of accelerated radiotherapy for localized invasive bladder cancer. Radiother Oncol 75 (2005) 34-43
18. Shipley W., Zietman A., Kaufman D., et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria invasive bladder cancer and who are cystectomy candidates-The Massachusetts General Hospital and Radiation Therapy Group experiences. Semin Radiat Oncol 15 (2004) 36-41
19. Coppin C.M., Gospodarowicz M.K., James K., et al. Improved local control of invasive bladder cancer by concurrent cisplatin and pre-operative or definitive radiation. J Clin Oncol 14 (1996) 2901-2907
20. Shipley W.U., Kaufman D.S., Tester W.J., et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97 suppl 8 (2003) 2115-2119
21. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG 85-12. Int J Radiat Oncol Biol Phys 25 (1993) 783-790
22. Kaufman D.S., Winter K.A., Shipley W.U., et al. The initial results in muscle invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-FU followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5 (2000) 471-476
23. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of RTOG phase III trial 8802. J Clin Oncol 14 (1996) 119-126
24. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. Eur Urol 48 (2005) 202-206
25. Kaufman D., Winter A., Shipley W., et al. Muscle invading bladder cancer, RTOG protocol 99-06: Initial report of phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy. J Clin Oncol 23 (2005) 397s (abstr 4506)
26. Chakravarti A., Winter K., Wu C., et al. Expression of the epidermal growth factor receptor (EGFR) and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the RTOG. Int J Radiat Oncol Biol Phys 62 (2005) 309-317
27. Kent E., Sandler H., Montie J., et al. Combined modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of phase I trial. J Clin Oncol 22 (2004) 2540-2545
28. Herman J., Smith D.C., Montie J., et al. Prospective quality of life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology 64 (2004) 69-73
29. Sangar V., McBain C., Lyons J., et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 61 (2005) 420-425
30. Salminen E. Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. Cancer 66 (1990) 2341-2345
31. Henningsohn L., Wijstrom H., Dickman P., et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 22 (1991) 111-117
32. Micaelson D., and Zietman A. Invasive bladder cancer: The role of bladder preserving therapy. Educational Brochure ASCO (2003) 457-465
33. Zietman A.L., Sacco D.E., Skowronki U.E., et al. Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: Urodynamic and quality of life evaluation of patients treated by trimodality therapy. Int J Radiat Oncol Biol Phys 54 suppl (2002) 62
34. Cauvet B., Lagrange J.L., Geoffrois L., et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer. Preliminary results of a French multicenter prospective study. Int J Radiat Oncol Biol Phys 57 suppl (2003) 177
35. Zietman A.L., Shipley W.U., Kaufman D.S., et al. Organ conserving approaches to muscle invasive bladder cancer: Future alternatives to radical cystectomy. Ann Med 32 (2000) 34-42
36. Zietman A.L., Grocela J., Zehr E., et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of Ta, T1 and Tis recurrence within the retained bladder. Urology 58 (2001) 380-385
37. Pieras E., Palou J., Salvador J., et al. Management and prognosis of transitional cell carcinoma. Superficial recurrence in muscle invasive bladder cancer after bladder preservation. Eur Urol 44 (2003) 222-225
38. Quek M., Stein J., Nichols P., et al. Prognostic significance of lymphvascular invasion of bladder cancer treated with radical cystectomy. J Urol 174 (2005) 103-106